U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06814158) titled 'Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer' on Feb. 03.
Brief Summary: Neoadjuvant ChemoRadioTherapy (NCRT) combined with surgical resection is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) based on CROSS and 5010 study. However, the recurrence and metastasis rate after neoadjuvant therapy is still very high, reaching about 40%, which seriously affects the long-term survival of patients after surgery. Therefore, how to improve the neoadjuvant therapy regimen, thereby increasing the pCR rate of ESCC patients, eliminating micro metastases and prolonging survival, has...